Neovacs to Expand Clinical Testing of its TNF-a Kinoid Lead Product Candidate
News Jun 29, 2009
Neovacs has announced that subject to regulatory consent, it plans to initiate a Phase II study of its TNF-a Kinoid later this year in rheumatoid arthritis patients who have failed treatment with at least one TNF-a inhibitor.
The decision to proceed with the trial was based on an initial review of encouraging data from the company’s Phase I/II study in Crohn’s disease.
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
New Speakers from Roche and Imperial College London Announced for SMi’s ADMET EventNews
SMi Group Reports: With less than 4 weeks left until the 13th annual ADMET Conference commences in London, SMi announces two new speakers joining the event.READ MORE